KROMATID Emphasizes Genomic Visibility Challenges in In Vivo Therapeutic Engineering

According to a recent LinkedIn post from KROMATID, the company is drawing attention to what it describes as a key risk in in vivo therapeutic engineering: limited visibility into genomic outcomes inside patients. The post contrasts in vivo approaches with ex vivo methods, suggesting that in vivo work shifts control from the lab to patient biology and reduces the ability to track which cells are edited and what structural genomic changes occur.

The company’s LinkedIn post highlights concerns that undetected genomic events could affect safety, durability, and patient trust in gene and cell therapies. The post positions KROMATID’s focus on single-cell, structural-level measurement as a potential answer to what it frames as a “visibility challenge” in in vivo therapy, implying that robust genomic integrity analytics could become an important enabling technology and potential revenue driver as the in vivo gene therapy market scales.